Show simple item record

dc.contributor.authorRichardsen, Elin
dc.contributor.authorAndersen, Sigve
dc.contributor.authorAl-Saad, Samer
dc.contributor.authorRakaee, Mehrdad
dc.contributor.authorNordby, Yngve
dc.contributor.authorPedersen, Mona Irene
dc.contributor.authorNess, Nora
dc.contributor.authorIngebriktsen, Lise
dc.contributor.authorFassina, Ambrogio
dc.contributor.authorTasken, Kristin Austlid
dc.contributor.authorMillls, Ian
dc.contributor.authorDønnem, Tom
dc.contributor.authorBremnes, Roy M.
dc.contributor.authorRasmussen Busund, Lill-Tove
dc.date.accessioned2019-10-07T08:49:42Z
dc.date.available2019-10-07T08:49:42Z
dc.date.issued2019-07-23
dc.description.abstractProstate cancer (PC) is a highly heterogenous disease and one of the leading causes of mortality in developed countries. Recently, studies have shown that expression of immune checkpoint proteins are directly or indirectly repressed by microRNAs (miRs) in many types of cancers. The great advantages of using miRs based therapy is the capacity of these short transcripts to target multiple molecules for the same- or different pathways with synergistic immune inhibition effects. miR-424 has previously been described as a biomarker of poor prognosis in different types of cancers. miR-424 is also found to target both the CTLA-4/CD80- and PD-1/PD-L1 axis. In the present study, the clinical significance of miR-424-3p expression in PC tissue was evaluated. Naïve radical prostatectomy specimens from 535 patients was used for tissue microarray construction. In situ hybridization was used to evaluate the expression of miR-424-3p and immunohistochemistry was used for CTLA-4 protein detection. In univariate- and multivariate analyses, low expression of miR-424-3p was significant associated with clinical failure-free survival, (p = 0.004) and p = 0.018 (HR:0.44, CI95% 0.22–0.87). Low expression of miR-424-3p also associated strongly with aggressive phenotype of PC. This highlight the importance of miR-424-3p as potential target for therapeutic treatment in prostate cancer.en_US
dc.description.sponsorshipNorwegian Cancer Societ Northern Health Administration UiT The Arctic University of Norwayen_US
dc.descriptionSource at <a href=https://doi.org/10.1038/s41598-019-47234-0>https://doi.org/10.1038/s41598-019-47234-0</a>.en_US
dc.identifier.citationRichardsen, E., Andersen, S., Al-Saad, S., Rakaee, M., Nordby, Y., Pedersen, M.I., ... Busund, L.T. (2019). Low Expression of miR-424-3p is Highly Correlated with Clinical Failure in Prostate Cancer. <i>Scientific Reports, 9</i>, 10662. https://doi.org/10.1038/s41598-019-47234-0en_US
dc.identifier.cristinIDFRIDAID 1714297
dc.identifier.doi10.1038/s41598-019-47234-0
dc.identifier.issn2045-2322
dc.identifier.urihttps://hdl.handle.net/10037/16337
dc.language.isoengen_US
dc.publisherSpringer Natureen_US
dc.relation.journalScientific Reports
dc.rights.accessRightsopenAccessen_US
dc.subjectVDP::Medical disciplines: 700::Clinical medical disciplines: 750::Oncology: 762en_US
dc.subjectVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Onkologi: 762en_US
dc.titleLow Expression of miR-424-3p is Highly Correlated with Clinical Failure in Prostate Canceren_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record